Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.83 USD
Change Today +0.14 / 0.95%
Volume 191.8K
PETX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 8:10 PM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

aratana therapeutics inc (PETX) Snapshot

Open
$14.67
Previous Close
$14.69
Day High
$14.95
Day Low
$14.26
52 Week High
03/6/15 - $20.63
52 Week Low
10/2/14 - $9.20
Market Cap
517.7M
Average Volume 10 Days
491.2K
EPS TTM
$-1.20
Shares Outstanding
34.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARATANA THERAPEUTICS INC (PETX)

Related News

No related news articles were found.

aratana therapeutics inc (PETX) Related Businessweek News

View More BusinessWeek News

aratana therapeutics inc (PETX) Details

Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide. Its product portfolio includes approximately 18 therapeutic candidates consisting of small molecule pharmaceuticals and large molecule biologics that target various opportunities in serious medical conditions in pets. The company develops AT-001, a prostaglandin E receptor 4 antagonist to treat the osteoarthritis pain in dogs, and degenerative joint disease in cats; AT-002, a ghrelin agonist for stimulation of appetite in dogs, as well as for weight gain in cats and dogs; AT-003, a bupivacaine liposome injectable suspension for the treatment of post-operative pain in cats and dogs; AT-004, a monoclonal antibody (MAB) used in the treatment of B-cell lymphoma in dogs; and AT-005, a caninized MAB for the treatment of T-cell lymphoma in dogs. It also develops other products, such as AT-006 for treatment of ocular lesions caused by feline herpes virus; AT-007 for the treatment of cats infected with feline immunodeficiency virus; AT-008, a small molecule for the treatment of canine lymphoma; AT-009, a caninized MAB used as an aid in the treatment of canine mast cell tumors; AT-010, a caninized MAB used as an aid for the treatment of atopic dermatitis in dogs; AT-011 to treat parvovirus in dogs; and AT-012 for treatment of feline calicivirus in cats. In addition, the company develops AT-015, a felinized MAB intended as an aid in the treatment of cat lymphoma; AT-016 that provides long-term relief of pain and disability caused by osteoarthritis through regeneration of joint damage; AT-017, a lymphoma immunotherapy for dog lymphoma; and AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Kansas City, Kansas.

49 Employees
Last Reported Date: 03/16/15
Founded in 2010

aratana therapeutics inc (PETX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer and Treasurer
Total Annual Compensation: $350.0K
Chief Development Officer
Total Annual Compensation: $302.5K
Chief Commercial Officer
Total Annual Compensation: $302.5K
Chief Scientific Officer
Total Annual Compensation: $321.9K
Compensation as of Fiscal Year 2014.

aratana therapeutics inc (PETX) Key Developments

Aratana Therapeutics Unveils Positive Pivotal Results for AT-002

Aratana Therapeutics announced positive results from its pivotal field effectiveness study of capromorelin, the company's innovative therapeutic for appetite stimulation in dogs. Capromorelin is a small molecule that mimics ghrelin, the naturally occurring hormone that stimulates appetite, increases body weight and increases serum growth hormone levels. In the pivotal field effectiveness study, dogs receiving a 3 mg/kg daily oral dose of capromorelin for four days demonstrated statistically significant increases in appetite compared to placebo. The study was a randomized, masked, placebo controlled multi-site study that enrolled over 200 inappetent dogs. Appetite was assessed with an owner questionnaire comparing appetite at baseline to appetite after four days of treatment. The pivotal field effectiveness study data are the final piece of the Effectiveness Technical Section that Aratana plans to submit to the Food and Drug Administration's Center for Veterinary Medicine as the Company pursues marketing approval for capromorelin. Based on current timelines for the FDA approval process, Aratana anticipates starting commercialization of capromorelin for treatment of inappetence in dogs in 2016.

Aratana Therapeutics, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 01:00 PM

Aratana Therapeutics, Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 01:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States. Speakers: Steven St. Peter, Co-Founder, Chief Executive Officer, President and Director.

Aratana Therapeutics, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 08:50 AM

Aratana Therapeutics, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 08:50 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Steven St. Peter, Co-Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PETX:US $14.83 USD +0.14

PETX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kindred Biosciences Inc $6.79 USD -0.07
View Industry Companies
 

Industry Analysis

PETX

Industry Average

Valuation PETX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 672.4x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 549.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARATANA THERAPEUTICS INC, please visit www.aratana.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.